Minzhen Xu
No más puestos en curso
Fortuna: 436 000 $ al 30/04/2024
Perfil
Minzhen Xu worked as a Vice President at NuGenerex Immuno-Oncology, Inc.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 27/09/2023 | 400 000 ( 5.95% ) | 436 000 $ | 30/04/2024 |
Antiguos cargos conocidos de Minzhen Xu.
| Empresas | Cargo | Fin |
|---|---|---|
| NUGENEREX IMMUNO-ONCOLOGY, INC. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
NuGenerex Immuno-Oncology, Inc.
 NuGenerex Immuno-Oncology, Inc. BiotechnologyHealth Technology NuGenerex Immuno-Oncology, Inc. is an oncology company focuses on the modulation of the immune system to treat cancer. It develops immunotherapeutic products and vaccines based on proprietary, patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) class II associated invariant chain that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The company was founded on October 8, 1993 and is headquartered in Miramar, FL. | Health Technology |
- Bolsa de valores
- Insiders
- Minzhen Xu
